Related Experiment Videos
[Basic study on interferon-beta: Part IV. Antitumor effect on nude mouse-transplanted human tumors]
Abstract:
The effects of human interferon-beta (IFN-beta, MR-21) on the growth of xenografted human tumors in nude mice were examined. IFN-beta was administered to mice with malignant melanoma (SK-MEL-28 and Sk-14) intratumorally at a dose of 1 X 10(5)-3 X 10(5) IU/mouse, with acute leukemia (CCRF-HSB-2) intratumorally at a dose of 3 X 10(5) IU/mouse, with glioblastoma (U-373 MG) intravenously or intratumorally at a dose of 1 X 10(5)-6 X 10(5) IU/mouse, or with uterine cervical tumor (HeLa S3) intravenously at a dose of 0.3 X 10(5)-1 X 10(5) IU/mouse. IFN-beta inhibited the growth of all of these tumors in a dose-dependent manner.
Insights
Human interferon-beta (IFN-beta) effectively inhibited the growth of various human tumors, including melanoma and glioblastoma, in nude mice. The anti-tumor effect was observed to be dose-dependent, highlighting IFN-beta's therapeutic potential.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Context:
- Investigating novel therapeutic agents for cancer treatment.
- Utilizing xenograft models to study human tumor growth in vivo.
- Exploring the role of interferons in cancer therapy.
Purpose:
- To evaluate the anti-tumor efficacy of human interferon-beta (IFN-beta) against a range of human cancers xenografted into nude mice.
- To determine the dose-dependent effects of IFN-beta on tumor growth inhibition.
Summary:
- Human interferon-beta (IFN-beta) was administered to nude mice bearing xenografted human tumors, including malignant melanoma, acute leukemia, glioblastoma, and uterine cervical tumor.
- IFN-beta was administered via intratumoral or intravenous routes at varying doses.
- A significant, dose-dependent inhibition of tumor growth was observed for all tested tumor types.
Impact:
- Demonstrates the broad-spectrum anti-tumor activity of IFN-beta in preclinical models.
- Suggests IFN-beta as a potential therapeutic candidate for multiple human cancers.
- Provides a basis for further clinical investigation of IFN-beta in cancer treatment.